Výsledky vyhledávání - "Mozhdeh Ahanfeshar-Adams"

Akademický článek

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

Autor: Shivshankari Rajkumar, Diana Berry, Kayla A. Heney, Colton Strong, LeeAnn Ramsay, Mathieu Lajoie, Rached Alkallas, Tan-Trieu Nguyen, Cameron Thomson, Mozhdeh Ahanfeshar-Adams, Matthew Dankner, Teresa Petrella, April A.N. Rose, Peter M. Siegel, Ian R. Watson

Publikováno v: Cell Reports, Vol 39, Iss 1, Pp 110634- (2022)

Summary: Although combination BRAF/MEK inhibition has produced significant survival benefits for BRAF p.V600 mutant melanomas, targeted therapies approved for BRAF non-p.V600 mutant melanomas remain limited. Through the analysis of 772 cutaneous mela

Externí odkaz: https://doaj.org/article/640812e1a89846ff8e8c5f518bbb3180

Zobrazit plný text záznamu

Supplementary Table S1 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Autor: Ian R. Watson, Tommy Alain, Dirk Schadendorf, Mathieu Lajoie, Mozhdeh Ahanfeshar-Adams, LeeAnn Ramsay, Tan-Trieu Nguyen

Supp Table S1. List of IFNγ pathway genes investigated for TCGA analysis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e722839c275561a44974232a32324fa
https://doi.org/10.1158/1078-0432.22479212

Zobrazit plný text záznamu

Supplementary Figure S4 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Autor: Ian R. Watson, Tommy Alain, Dirk Schadendorf, Mathieu Lajoie, Mozhdeh Ahanfeshar-Adams, LeeAnn Ramsay, Tan-Trieu Nguyen

Supp Figure S4. JAK1/2 inhibitor Ruxolitinib increases melanoma sensitivity to VSV-d51

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bd526f4ce3b867fbc53920767741cd3
https://doi.org/10.1158/1078-0432.22479218

Zobrazit plný text záznamu

Data from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Autor: Ian R. Watson, Tommy Alain, Dirk Schadendorf, Mathieu Lajoie, Mozhdeh Ahanfeshar-Adams, LeeAnn Ramsay, Tan-Trieu Nguyen

Purpose:Next-generation sequencing studies and CRISPR-Cas9 screens have established mutations in the IFNγ-JAK-STAT pathway as an immune checkpoint inhibitor (ICI) resistance mechanism in a subset of patients with melanoma. We hypothesized ICI resist

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284f140a8f55622caf1f3b658ef8e365
https://doi.org/10.1158/1078-0432.c.6530153

Zobrazit plný text záznamu

Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

Autor: Mozhdeh Ahanfeshar-Adams, Dirk Schadendorf, Tan-Trieu Nguyen, LeeAnn Ramsay, Mathieu Lajoie, Ian R. Watson, Tommy Alain

Publikováno v: Clinical Cancer Research. 27:3432-3442

Purpose: Next-generation sequencing studies and CRISPR-Cas9 screens have established mutations in the IFNγ-JAK-STAT pathway as an immune checkpoint inhibitor (ICI) resistance mechanism in a subset of patients with melanoma. We hypothesized ICI resis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88f2cf3ce08016c7a297b6d1857db047
https://doi.org/10.1158/1078-0432.ccr-20-3365

Zobrazit plný text záznamu

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

Publikováno v: Cell reports. 39(1)

Although combination BRAF/MEK inhibition has produced significant survival benefits for BRAF p.V600 mutant melanomas, targeted therapies approved for BRAF non-p.V600 mutant melanomas remain limited. Through the analysis of 772 cutaneous melanoma exom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d92cafa7a32e1bf669270cfaf6b133f1
https://pubmed.ncbi.nlm.nih.gov/35385748

Zobrazit plný text záznamu

Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma

Autor: Mozhdeh Ahanfeshar-Adams, Jonathan H. Zippin, Rached Alkallas, Hamed S. Najafabadi, Ian R. Watson, Karen Vo Hoang, Marine Lingrand, Dan Moldoveanu, Philippe Lefrançois, Alan Spatz, Kevin Watters, Mathieu Lajoie

Publikováno v: Nat Cancer

The high background tumor mutation burden in cutaneous melanoma limits the ability to identify significantly mutated genes (SMGs) that drive this cancer. To address this, we performed a mutation significance study of over 1,000 melanoma exomes, combi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09c4849b0ff72e667a360b49ee2ba46e
https://pubmed.ncbi.nlm.nih.gov/35121978

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání